Format

Send to

Choose Destination
Muscle Nerve. 2016 Jun;53(6):872-6. doi: 10.1002/mus.24960. Epub 2015 Nov 26.

Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.

Author information

1
Department of Medicine, Division of Physical Medicine and Rehabilitation, Lyndhurst Centre, Toronto Rehabilitation Institute, 520 Sutherland Drive, Room 205, Toronto, Ontario, M4G 3V9, Canada.
2
Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada.
3
Division of Neurology, University Health Network, Toronto, Ontario, Canada.

Abstract

INTRODUCTION:

Myasthenia gravis (MG) exacerbations may be treated with intravenous immunoglobulin (IVIg) or plasma exchange (PLEX), which have equivalent effectiveness. This cost-minimization analysis compared IVIg with PLEX for treatment of patients with MG exacerbation.

METHODS:

We combined the Ontario-based health cost data with clinical data from a randomized clinical trial. Analyses were undertaken from the perspective of a public healthcare insurer and from the perspective of a tertiary university hospital payer.

RESULTS:

PLEX was less costly than IVIg among patients with a body mass index (BMI) > 15.7 kg/m(2) , from the perspective of the public healthcare insurer (P < 0.0001). However, PLEX was more costly than IVIg from the perspective of the hospital payer when the costs of blood products were excluded (P < 0.0001).

CONCLUSIONS:

PLEX can be considered a short-term cost-minimizing therapy when compared with IVIg for treatment of MG exacerbation among patients with BMI >15.7 kg/m(2) , from the perspective of a public healthcare insurer. Muscle Nerve 53: 872-876, 2016.

KEYWORDS:

cost-minimization analysis; intravenous immunoglobulin; myasthenia gravis; neuromuscular junction disease; plasma exchange

PMID:
26521889
DOI:
10.1002/mus.24960
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center